Summary
Nivolumab is a treatment option for patients with metastatic renal cell carcinoma (RCC) previously treated with targeted antiangiogenic therapy. Papillary renal cell carcinoma (PRCC) comprises 10–15% of RCC cases but non-clear cell subtypes were excluded from the immunotherapy trials. We report the case of a woman with recurrent metastatic PRCC who had an impressive therapeutic response to nivolumab with no significant adverse events. She had previously been treated with sunitinib and pazopanib with no response. She showed a remarkable clinical improvement after only the first 2 immunotherapy cycles and subsequent radiographic studies demonstrated a marked decrease in tumor burden. At present, she continues to show a durable benefit after 8 months of treatment. Her tumor had <1% positivity for PD-L1 staining and a low tumor mutational burden with no actionable mutations on genomic sequencing. Considering its high genetic variation, checkpoint blockade immunotherapies (CBIs) are attractive treatment options in PRCC. This is the third case that reports objective responses of nivolumab in PRCC. We believe our patient’s experience supports the inclusion of non-clear cell RCC on clinical trials using CBIs. PD-L1 status and TMB may not serve as predictive biomarkers for response.
Similar content being viewed by others
References
Motzer RJ, Escudier B, McDermott DF et al (2015) Nivolumab versus Everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1803–1813
The Cancer Genome Atlas Research Network. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. (2016). N Engl J Med 374:135–45
Decastro GJ, McKiernan JM (2008) Epidemiology, clinical staging, and presentation of renal cell carcinoma. Urol Clin North Am 35:581–592
Godwin JL, Zibelman M, Plimack ER, Geynisman DM (2014) Immune checkpoint blockade as a novel immunotherapeutic strategy for renal cell carcinoma: a review of clinical trials. Discov Med 18:341–350
Geynisman DM (2015) Anti-programmed cell death protein 1 (PD-1) antibody nivolumab leads to a dramatic and rapid response in papillary renal cell carcinoma with sarcomatoid and rhabdoid features. Eur Urol 68(5):2015–2017
Ruiz-Bañobre J, Anido U, Abdulkader I et al (2016) Long-term response to Nivolumab and acute renal failure in a patient with metastatic papillary renal cell carcinoma and a PD-L1 tumor expression increased with Sunitinib therapy: a case report. Front Oncol 6:250
Valenca LB, Hirsch MS, Choueiri TK, Harshman LC (2015) Non-clear cell renal cell carcinoma. Part 2: therapy. Clin Adv Hematol Oncol 13(6):383–391
National Comprehensive Cancer Network. Kidney cancer version 2 (2017) https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf. Accessed 17 March 2017
Vera-Badillo FE, Templeton AJ et al (2015) Systemic therapy for non-clear cell renal cell carcinomas: a systematic review and meta-analysis. Eur Urol 67(4):740
McDermott DF, Motzer RJ, Atkins MB, Plimack ER, Sznol M, George S et al (2016) Long-term overall survival (OS) with nivolumab in previously treated patients with advanced renal cell carcinoma (aRCC) from phase I and II studies. J Clin Oncol 34(suppl):abstr 4507
Choueiri TK, Fay AP, Gray KP et al (2014) PD-L1 expression in nonclear-cell renal cell carcinoma. Ann Oncol 25:2178–2184
Cho DC, Sosman JA, Sznol M et al (2013) Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC) [ASCO abstract 4505]. J Clin Oncol 31(15 suppl)
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Diego Adrianzen Herrera declares that he has no conflict of interest. Sarah Fleisig declares that she has no conflict of interest. Benjamin Gartrell declares that he has no conflict of interest.
Funding
This work received no specific grant from any funding agency in the public, commercial or non-for-profit sectors.
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Informed consent
Informed consent was obtained from the patient reported in this manuscript.
Rights and permissions
About this article
Cite this article
Adrianzen Herrera, D.A., Fleisig, S.B. & Gartrell, B.A. Impressive and durable response to nivolumab in a patient with metastatic type 2 papillary renal cell carcinoma: On-label but without evidence. Invest New Drugs 35, 665–668 (2017). https://doi.org/10.1007/s10637-017-0469-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-017-0469-5